REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer?
Disease control TerminatedThis early-stage study tested a new drug, KRT-232, added to a standard three-drug combination for multiple myeloma that has come back or stopped responding to treatment. The main goals were to find the safest dose and see how well the body handles the four-drug combination. It in…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Personalized cell therapy tested for Tough-to-Treat blood cancer
Disease control TerminatedThis early-stage study tested the safety of a personalized cell therapy called Descartes-15 for patients with advanced multiple myeloma that has returned or stopped responding to other treatments. The therapy involves modifying a patient's own immune cells to target the cancer. T…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC